![](https://cdn.sanity.io/images/0vv8moc6/onclive/d76f6e4ce1f998a2342f01892cc8b9dda4853fdb-200x200.jpg?fit=crop&auto=format)
IDE937 Generates Responses in NSCLC and Urothelial Cancer Harboring MTAP Deletions
Treatment with the potent, selective, potential first-in-class MAT2A inhibitor IDE397 induced responses in patients with locally advanced or metastatic urothelial cancer or non–small cell lung cancer (NSCLC) harboring MTAP deletions, according to results …